Mitochondrial Dysfunction in Systemic Lupus Erythematosus with a Focus on Lupus Nephritis
International Journal of Molecular Sciences · 03.06.2024 · 25 (11) · 6162
DOI: 10.3390/ijms25116162 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 03.06.2024. Verfasst von Matthieu Halfon und 2 weiteren Autor:innen. Beteiligte Einrichtung: Transplantation Center, Lausanne University Hospital, Rue du Bugnon 44, CH-1010 Lausanne, Switzerland. Hauptthemen laut MEDLINE: Lupus Nephritis, Mitochondria, Lupus Erythematosus, Systemic. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of medicine and laboratory of Lausanne university hospital., Department of medicine and laboratory of Lausanne university hospital.
Abstract (Originalsprache)
Systemic lupus erythematosus (SLE) is an autoimmune disease affecting mostly women of child-bearing age. Immune dysfunction in SLE results from disrupted apoptosis which lead to an unregulated interferon (IFN) stimulation and the production of autoantibodies, leading to immune complex formation, complement activation, and organ damage. Lupus nephritis (LN) is a common and severe complication of SLE, impacting approximately 30% to 40% of SLE patients. Recent studies have demonstrated an alteration in mitochondrial homeostasis in SLE patients. Mitochondrial dysfunction contributes significantly to SLE pathogenesis by enhancing type 1 IFN production through various pathways involving neutrophils, platelets, and T cells. Defective mitophagy, the process of clearing damaged mitochondria, exacerbates this cycle, leading to increased immune dysregulation. In this review, we aim to detail the physiopathological link between mitochondrial dysfunction and disease activity in SLE. Additionally, we will explore the potential role of mitochondria as biomarkers and therapeutic targets in SLE, with a specific focus on LN. In LN, mitochondrial abnormalities are observed in renal cells, correlating with disease progression and renal fibrosis. Studies exploring cell-free mitochondrial DNA as a biomarker in SLE and LN have shown promising but preliminary results, necessitating further validation and standardization. Therapeutically targeting mitochondrial dysfunction in SLE, using drugs like metformin or mTOR inhibitors, shows potential in modulating immune responses and improving clinical outcomes. The interplay between mitochondria, immune dysregulation, and renal involvement in SLE and LN underscores the need for comprehensive research and innovative therapeutic strategies. Understanding mitochondrial dynamics and their impact on immune responses offers promising avenues for developing personalized treatments and non-invasive biomarkers, ultimately improving outcomes for LN patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Transplantation Center, Lausanne University Hospital, Rue du Bugnon 44, CH-1010 Lausanne, Switzerland.
- Division of Immunology and Allergy, Lausanne University Hospital, CH-1010 Lausanne, Switzerland.
ORCID-Profile: Camillo Ribi
Förderung
- Department of medicine and laboratory of Lausanne university hospital.
- Department of medicine and laboratory of Lausanne university hospital
Zitieren
APA
Halfon, M., Tankeu, A. T., & Ribi, C. (2024). Mitochondrial Dysfunction in Systemic Lupus Erythematosus with a Focus on Lupus Nephritis. International Journal of Molecular Sciences, 25(11), 6162. https://doi.org/10.3390/ijms25116162
Vancouver
Halfon M, Tankeu AT, Ribi C. Mitochondrial Dysfunction in Systemic Lupus Erythematosus with a Focus on Lupus Nephritis. International Journal of Molecular Sciences. 2024;25(11):6162. doi:10.3390/ijms25116162
BibTeX
@article{Halfon2024,
author = {Halfon, Matthieu and Tankeu, Aurel T and Ribi, Camillo},
title = {Mitochondrial Dysfunction in Systemic Lupus Erythematosus with a Focus on Lupus Nephritis},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {11},
pages = {6162},
doi = {10.3390/ijms25116162}
}
EUVIMED